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Background: The role of adjuvant radiotherapy (RT) for patients with stage III thymoma after complete resection is
not definite. Some authors have advocated postoperative RT after complete tumor resection, but some others
suggested observation. In this study, we retrospectively evaluated the effect of postoperative RT on survival as well
as tumor control in patients with Masaoka stage III thymoma.
Methods: Between June 1982 and December 2010, 65 patients who underwent complete resection of stage III
thymoma entered the study. Fifty-three patients had adjuvant RT after surgery (S + R) and 12 had surgery only (S
alone). Of patients who had adjuvant RT, 28 had three-dimensional conformal RT (3D-CRT)/intensity modulated RT
(IMRT) and 25 had conventional RT. A median prescribed dose of 56 Gy (range, 28–60 Gy) was given.
Results: The median follow-up time was 50 months (range, 5–360 months). Five- and 10-year overall survival (OS)
rates were 91.7% and 71.6%, respectively, for S + R and 81.5% and 65.2% for S alone (P = 0.5), respectively. In the
subgroup analysis, patients with 3D-CRT/IMRT showed a trend of improved 5-year OS rate compared with conventional
RT (100% vs. 86.9%, P =0.12). Compared with S alone, the 5-year OS rate was significantly improved (100% vs. 81.5%,
P = 0.049). Relapses occurred in 15 patients (23.1%). There was a trend of lower crude local recurrence rates for S + R
(3.8%) compared with S alone (16.7%) (P = 0.09), whereas the crude regional recurrence rates were similar (P = 0.9).
No clear dose–response relationship was found according to prescribed doses.
Conclusions: Adjuvant 3D-CRT/IMRT showed potential advantages in improving survival and reducing relapse in
patients with stage III thymoma after complete resection, whereas adjuvant RT did not significantly improve survival
or reduce recurrence for the cohort as a whole. Doses of ≤ 50 Gy may be effective and could be prescribed for
adjuvant RT. To confirm the role of adjuvant 3D-CRT/IMRT in patients who undergo a complete resection of
thymoma, a multicenter randomized study should be performed.
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Although thymoma is rare, it is one of the most com-
mon mediastinal neoplasms and surgery remains the
main therapeutic modality. Radiotherapy (RT) has also
been recommended as an adjuvant therapy to reduce the
rate of local and regional failure after incomplete or* Correspondence: qinfufeng19@163.com
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reproduction in any medium, provided the orcomplete resection [1-4]. This is especially true in
Masaoka stage III thymomas because of the involvement
of surrounding vital structures [2,3,5]. However, the op-
timal management of these tumors remains unknown.
Three-dimensional conformal RT (3D-CRT)/intensity
modulated RT (IMRT) has been used to treat tumors
with reduced damage to normal tissues and increased
tumor control and survival rates. Therefore, further in-
vestigation into the value of adjuvant RT is warranted,
especially with the use of 3D-CRT/IMRT for stage III
thymoma after complete resection. Here, we reviewed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Between June 1982 and December 2010, 119 patients
with stage III thymoma according to the Masaoka and
modified Masaoka staging system [6,7] were treated at
the Cancer Hospital of the Peking Union Medical
College, Chinese Academy of Medical Science.
Of these patients, 70 underwent complete tumor re-
section; one patients were excluded from the study due
to incomplete records and the other 4 were excluded
due to preoperative RT followed by surgery and postop-
erative RT. The remaining 65 patients were enrolled for
the analysis. This retrospective study was approved by
our Institutional Review Board. The dates of follow-up
appointments were obtained through a review of the
hospital records, in addition to telephone, interviews
and patient consultations. Patients with thymic carcin-
oma or carcinoid were excluded from this study.
Pathologic review
Due to the possibility of invasion into surrounding struc-
tures, such as blood vessels, pericardium and lung, surgi-
cal notes were reviewed carefully to determine the
completeness of tumor resection. Adhesion of the tumor
to adjacent structures was not considered as confirmed
invasion. Pathology reports were obtained and reviewed
for all patients. Slides of surgical specimens were avail-
able for 63 of the 65 patients; these were reviewed by an
experienced pathologist and classified as type A (n = 2),
type B1 (n = 12), type B2 (n = 28), type B3 (n = 14) or
type AB (n = 7) according to the WHO histopathological
classification [8].
Surgery
All of the 65 patients underwent complete tumor resection
with negative surgical margins, including pericardiectomy,
wedge resection of the lung, phrenicectomy or vein resec-
tion followed by replacement surgery when these surround-
ing structures were involved. Twelve patients (18.5%)
received surgery only (S alone), and 53 patients (81.5%)
received adjuvant RT after surgery (S + R).
Radiotherapy
Of the patients who received postoperative RT, 25 patients
had conventional RT and 28 patients had 3D-CRT/IMRT
(6 patients with 3D-CRT, 22 patients with IMRT). The se-
lection of patients for adjuvant RT was based principally
on the surgeons’ judgments.
The radiation target volume was defined using pre-
operative images to identify the tumor extent or usingmetal marks placed during surgery. Fifty-one patients
were treated with involved field, whose clinical target
volume (CTV) was defined as tumor bed with margins
extension of 1–2 cm; only 2 patients were treated with
extended field, whose CTV was defined as the whole
mediastinum with the upper and lower margins at the
thoracic inlet and the diaphragmatic crurae, respectively.
Both planning target volume (PTV) of involved field and
extended field were defined as CTV plus a 0.5-1 cm
margin.
A median prescribed dose of 56 Gy to PTV (range,
28–60 Gy) was given in 2-Gy daily fractions. Three pa-
tients received less than 30 Gy because of severe toxic-
ities (2 patients) or unknown reason (one patient).
Conventional RT was delivered with 6 or 8-MV photons
from linear accelerators using an anteroposterior op-
posed field or angled anterior fields, with the spinal cord
dose limited to 45 Gy. Two anterior, wedged portals or
off-cord, oblique, opposed portals were often used to
provide a boost to the anterior mediastinum to higher
doses. Patients who were administered with 3D-CRT or
IMRT all underwent computed tomography (CT) simu-
lation (slice thickness of 5 mm) while immobilized in
the supine position using a thermoplastic resin shells.
Doses were delivered using a step-and-shoot technique
with 6-MV photons from a linear accelerator with the
forward (3D-CRT) or the inverse (IMRT) Pinnacle3
planning systems (Philips Healthcare, Madison, WI,
USA), and at least 95% PTV received the prescribed
dose.
Chemotherapy
Two patients received adjuvant chemotherapy after sur-
gery and RT. One was given two cycles of gemcitabine
and cisplatin after resection; the regimen of the other
patient was unknown.
Follow-up
The last follow-up date was June 25th, 2012. Physical
examination, abdominal ultrasonography, chest radiog-
raphy and/or chest CT was performed every 3 or
6 months after treatment. The median follow-up time
was 50 months (range, 5–360 months). Survival was cal-
culated from the date of surgery. Disease-free survival
(DFS) refers to the time from surgery to recurrence,
disease-specific survival (DSS) refers to the time from
surgery to tumor-induced death, and overall survival
(OS) refers to the time from surgery to death from any
cause.
Statistical analysis
All analyses were conducted using SPSS 17.0 statistical
software (SPSS, Chicago, IL, USA). The Kaplan–Meier
method was used to estimate the survival rates and
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Twenty-two patients had accompanying symptoms of
myasthenia gravis (MG) and two had pure red cell
aplasia. The invasion of surrounding structures was as
follows: lung in 29 patients, pericardium in 44, large
veins in 18, large arteries in 3 and phrenic nerve in 18.
In some patients, multiple structures were involved.
Patient characteristics were similar between those who
had adjuvant RT and those who underwent surgery
alone (Table 1).
Survival
By the last follow-up date, 12 (18.5%) patients had died.
Six died of tumor relapse, one from second primary ma-
lignant tumor, one from lung fibrosis caused by severe
radiation pneumonitis, one from MG and three for un-
related reasons. The 5- and 10-year OS rates were 89.7%Table 1 Characteristics of patients
Characteristic S + R S alone χ2 P
n = 53(%) n = 12(%)
Sex 0.3 0.6
Male 26(49.1%) 7 (58.3%)
Female 27(50.9%) 5 (41.7%)
Age 0.0 0.9
>48 22(41.5%) 5 (41.7%)
≤ 48 31(58.5%) 7 (58.3%)
pathologic type 0.4 0.5
B3 13(24.5%) 4 (33.3%)
Other subtypes 40(75.5%) 8 (66.7%)
Tumor size 0.4 0.8
≤ 7cm 25(49.1%) 5 (41.7%)
>7cm 28(50.9%) 7 (58.3%)
Myasthenia Gravis 0.007 0.9
Presence 17(32.1%) 4 (33.3%)
Absence 36(67.9%) 8 (66.7%)
Multistructure invasion 0.003 0.9
Presence 26(49.1%) 6 (50.0%)
Absence 27(50.9%) 6 (50.0%)
Pleural effusion 1.5 0.2
Presence 6(11.3%) 0 (0.0%)
Absence 47(88.7%) 12 (100.0%)
S + R indicates surgery and radiotherapy; S, surgery.(95% confidential interval [CI], 85.1-94.3%) and 70.3%
(95% CI, 61–79.6%), respectively, the 5- and 10-yr DFS
were 76.9% (95% CI, 70.1-83.7%) and 53.2% (95% CI,
43.1-63.3%), respectively, and the 5- and 10-year DSS
were 96.0% (95% CI, 93.2-98.8%) and 80.3% (95% CI,
71.6-89%), respectively.
Five- and 10-yr OS rates were 91.7% (95% CI, 86.9-
96.5%) and 71.6% (95% CI, 60.6-82.6%) in the S + R
group and 81.5% (95% CI, 70.6-93.4%) and 65.2% (95%
CI, 47.8-82.6%) in the S alone group (P =0.8; Hazard ra-
tio [HR], 0.89; 95% CI, 0.22-3.5) (Figure 1). Five- and 10-
yr DFS rates were 75.7% (95% CI, 67.8-83.6%) and 55.4%
(95% CI, 43.6-67.2%) in the S + R group and 80.8% (95%
CI, 68.6-93%) and 48.5% (95% CI, 29.3-67.7%) in the S
alone group (P =0.7; HR, 0.78; 95% CI, 0.23-2.6)
(Figure 2). Five- and 10-yr DSS rates were 97.9% (95%
CI, 95.8-100%) and 83.4% (95% CI, 73.6-93.2%) in the
S + R group and 88.9% (95% CI, 78.4-99.4%) and 71.1%
(95% CI, 53.1-89.1%) in the S alone group (P =0.7; HR,
0.7; 95% CI, 0.11-4.4) (Figure 3).
In subgroup analysis, patients with 3D-CRT/IMRT
had a trend of improved 5-yr OS rate (100%) compared
with conventional RT (86.9% [95% CI, 79.8-94%]) (P =
0.12; HR, 4.7; 95% CI, 0.66-33.61), and a improved 5-yr
OS rate when in pairwise compared with S alone (P =
0.049). Difference of OS rates was not statistically sig-
nificant when these three subgroups were compared in
pooled (P = 0.28). The 5-yr DFS and 5-yr DSS rates for
patients with 3D-CRT/IMRT and conventional RT were
73.8% (95% CI, 64.5-83.1%) and 67.5% (95% CI, 46.8-
88.2%) (P = 0.35; HR, 1.9; 95% CI, 0.49-7.38), and 100%
and 96% (95% CI, 92.1-99.9%) (P = 0.28; HR, 4.7; 95% CI,
0.28-7.8), respectively. When compared in pooled with S
alone, the difference of 5-yr DFS and DSS rates were notFigure 1 Comparison of overall survival between surgery and
adjuvant radiotherapy (S + R) and surgery alone (S alone)
groups.
Figure 2 Comparison of disease-free survival between surgery
and adjuvant radiotherapy (S + R) and surgery alone (S alone)
groups.
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spectively). No patients treated with 3D-CRT or IMRT
died till the date of follow-up, and patients with IMRT
showed a similar 5-yr DFS rate compared with patients
with 3D-CRT (80% [95% CI, 62.1-97.9%] vs.75% [95%
CI, 53.3-96.7%], P = 0.32).
Recurrence and salvage treatment
During the follow-up period, 15 patients (23.1%) had
relapses (Table 2). Four had local recurrence (tumor bed
or in-field recurrence) at the first recurrence, ten had
regional recurrence (out-field recurrence) at the first
recurrence (including chest wall, pleural, mediastinum,
diaphragm and lung) and one had both regionalFigure 3 Comparison of disease-specific survival between
surgery and adjuvant radiotherapy (S + R) and surgery alone
(S alone) groups.recurrence (chest wall) and distant metastasis (bone) at
first recurrence simutaneously. The median time to re-
currence was 40 months (range, 9–99 months).
From Table 2, it can be seen that there was a trend of
lower crude local recurrence rates for S + R (3.8%) com-
pared with S alone (16.7%) (P = 0.09), whereas the crude
regional recurrence were similar (P = 0.9). The first site
of recurrence for different radiation techniques was
listed in Table 3. Conventional RT seemed to have more
out-field recurrence compared with 3D-CRT/IMRT,
which yet needs further follow-up for the shorter median
follow-up time in patients with 3D-CRT/ IMRT.
Eight patients underwent salvage treatment and seven
received no further treatment after tumor recurrence.
Five patients survived disease-free after salvage treat-
ment; two of these underwent surgical resection, two
had RT, and one received sequential chemotherapy and
RT. The survival time after recurrence was 13–
300 months. Two patients survived with disease after RT
alone and one with sequential chemotherapy and RT.
Two died of tumor relapse at 24 and 60 months after
salvage retreatment and the other has been living with
tumor for 27 months. Of the patients without salvage
treatment, three patients died of tumor at 3, 5 and
12 months and the other four have been living with their
tumor (median survival, 13 months) since the relapse
was diagnosed.
Radiation dose–response relationship
Fifty-one patients for whom radiation doses were known
were subjected to further analysis. The number of pa-
tients given doses of ≤ 50 Gy and >50 Gy were 20 and
31, respectively. The 5-yr and 10-yr OS rates for patients
given doses of ≤ 50 Gy were 94.7% (95% CI, 89.6-89.8%)
and 65% (95% CI, 47-83%), and 88.8% (95% CI, 80.9-
96.7%) and 58.2% (95% CI, 39–77.4%) for patients
given >50 Gy (P = 0.7; HR, 0.7; 95% CI, 0.16-3.15). The
5-yr and 10-yr DFS rates were 73.9% (95% CI, 62.1-
85.7%) and 46.2% (95% CI, 28.8-63.6%) for patients given
doses of ≤ 50 Gy, and 73.2% (95% CI, 60.7-85.7%) and
54.9% (95% CI, 36.5-63.3%) for patients given >50 Gy
(P = 0.67; HR, 1.33; 95% CI, 0.39-4.26). Higher doses did
not achieved a higher survival from the current analysis.
Table 3 presents the incidence and sites of recurrence
according to radiation doses and the irradiated field.
Though no survival benefit was showed with higher
doses, the cude regional recurrence rates tended to de-
crease with doses >50 Gy, but the difference was not sta-
tistically significant (P = 0.2). Two of 31 patients with
doses >50 Gy and 3 of 20 patients with doses of ≤ 50 Gy
developed pleura recurrences that higher dose may be
benefitial for control of pleura recurrence. Meanwhile,
two patients developed in-field recurrence. One of them
was marginal recurrence with a dose of >50 Gy using








First recurrence sites (%)
PL MS CW Lung DP DM
S + R 53 2 (3.8) 9 (17.0) 5 (9.4) 2 (3.8) 2 (3.8) 1 (1.9) 0 1 (1.9)
S alone 12 2 (16.7) 2 (16.7) 1 (8.3) 0 0 1 (8.3) 1 (8.3) 0
S + R indicates surgery plus radiotherapy, S, surgery; LR, local recurrence; RR, regional recurrence; PL, pleura; MS, mediastinum; CW, chest wall; DP, diaphragm; DM,
distant metastasis.
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field with a dose of 50 Gy using conventional RT. The
crude local failure rates were low in both the two groups
that a lower dose of 50 Gy may abtain a good local
control.
Treatment-related toxicity
Five patients (9.4%), comprising four who underwent
conventional RT (7.5%) and one who received 3D-
CRT/IMRT (1.9%), developed symptomatic radiation
pneumonitis. One 69 year old patient with poor pulmon-
ary function developed grade III acute severe pneumon-
itis (RTOG grading) which was exacerbated by bacterial
lung infection when delivered dose of 28 Gy using
conventional RT (he received no further dose of RT).
This patient was treated using steroids and antibiotics
and symptoms got relieved to a certain extent, but not
complete remission. Finally, he died of radiation
pneumonitis-related lung fibrosis 10 months later. The
total dose to PTV for other 4 patients who developed
grade II radiation pneumonitis was all 60 Gy. Three
patients developed pericarditis after conventional RT, in-
cluding two patients with grade I that required no treat-
ment and one with grade II that required conservative
treatment. One patient refused further treatment for
grade IV radiation-related agranulocytosis when deliv-
ered dose of 28Gy.
Discussion
The incidence of thymoma is rare, but it can present as
a benign lesion or a highly infiltrative and even a metas-








≤ 50 Gy 20 1 (5) 5 (25)
> 50Gy 31 1 (3.2) 4 (12.9)
Technique
Conventional RT 25 1 (4) 8 (32)
3D-CRT/IMRT 28 1 (3.6) 1 (3.6)
RT indicates radiotherapy; 3D-CRT/IMRT, three dimensional conformal radiotherapy
recurrence; PL, pleura; MS, mediastinum; CW, chest wall; DP, diaphragm.stage III thymoma, despite the involvement of adjacent
structures, and only 60% have a complete resection. Pre-
vious studies have reported the 5-yr and 10-yr OS rates
of patients with stage III thymoma to be 60–80% and
50–70%, respectively [10-12]. Survival is improved after
complete tumor resection compared with incomplete re-
section [1,2,13]. Adjuvant RT is generally used and is
beneficial for patients with an incompletely resected
tumor. However, definitive evidence regarding the bene-
fit to patients of adjuvant radiotherapy after complete
tumor resection are lacking, as there have been no pro-
spective trials or higher quality retrospective studies.
Curran and colleagues recommended that adjuvant RT
should be given for stage III thymoma after complete re-
section [2]. However, in their study, only four patients
received postoperative RT, and therefore their results
were less convincing. Eralp et al. also reported that adju-
vant RT improved the OS and DFS rates for 36 patients
with thymoma, but all stages of thymoma and both com-
pletely or incompletely resected tumors were included in
their study [14]. However, Ruffini et al. reported the re-
sults of a series of 53 patients with stage III thymoma
after complete resection, including 17 patients who were
given postoperative RT and 36 who underwent surgery
alone [15]. They observed higher recurrence rates and
worse survival rates in patients who received adjuvant
RT than surgery alone (P = 0.02). In a Japanese study, of
78 patients who received postoperative RT and 31 pa-
tients who underwent surgery alone after complete
tumor resection, total recurrence rates were 23% and
26%, and local recurrence rates were 5.1% and 3.1%, re-
spectively [12]. Adjuvant RT also conferred no benefitadiotherapy mode
First recurrence sites (%)
PL MS CW Lung DP
3 (15) 1 (5) 1 (5) 1 (5) 1 (5)
2 (6.4) 1 (3.2) 1 (3.2) 0 0
0
4 (16) 2 (8) 2 (8) 1 (3.6) 1 (3.6)
1 (3.6) 0 0 0 0
or intensity modulated radiotherapy; IFR, in-field recurrence; OFR, out-field
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tion. A meta-analysis reviewed data from 122 patients
with stage III thymoma in order to determine the role of
adjuvant RT after tumor resection in reducing recur-
rence and improving survival [16]. The risk of recur-
rence was 0–64% with adjuvant RT (53 patients) and
13–80% with S alone (69 patients) (P = 0.8, odd ratio =
0.87, 95% CI: 0.18–4.13). However, the heterogeneity
among studies for stage III thymomas was significant
(P = 0.02), and therefore the value of this meta-analysis
study was not strong and the role of adjuvant RT was
not confirmed. In the present study, the total recurrence
rates had no significant decrease in patients with S + R
compared with S alone, though adjuvant RT had a trend
of reducing local recurrence (P = 0.09). These results
were similar to those of previous studies that showed ad-
juvant RT had no significant effect on reducing the re-
currence rate of stage III thymoma after complete
resection [1,2,10-12,15,17].
In 2011, Patel and colleagues reported the results of
1,464 patients with a thymic malignancy from centers
that participated in the Surveillance, Epidemiology, and
End Results (SEER) program [18]. Among patients who
did not receive RT, the 10-year OS rate was 41% com-
pared with 42% for those who did receive RT (P = 0.06).
The median OS for the patients who did not receive RT
was 80 months compared to 97 months for those who
did receive RT. In patients with Masaoka stage II–III
malignancy, OS was significantly improved with RT (P =
0.002), and a trend in improved cause specific survival
(CSS) was observed (P = 0.1). However, in patients who
underwent total excision, the 5- and 10-year OS rates
were 75% and 53%, respectively, for those who received
RT, versus 71% and 55%, respectively, for those who did
not (P = 0.1). The 5- year and 10-year CSS rates for
those with a total excision were 93% and 83%, respect-
ively, for patients who received RT, versus 92% and 78%
for those who did not receive RT (P = 0.1). This report
was lacking the definitive evidence of the benefit in pa-
tients after complete tumor resection for adjuvant radio-
therapy, but there were benefit for all of the patients.
From the above retrospective studies, we can conclude
that the role of adjuvant RT in patients with stage III
thymoma after complete resection was not confirmed as
a result of some limiting factors, including small sample
sizes, a prolonged time for sample collection, different
histological categories and different stages included in
the same study, heterogeneity of data for multicenter
studies, and the use of conventional RT alone. As a re-
sult, the subgroup analysis would be difficult due to vari-
ations in treatment and comparability between reports.
Despite a large sample size the study by Patel et al., and
the fact the SEER database is a national cancer registry
for approximately 26% of the US population and 17geographically defined registries between 1973 and 2003,
similar problems also existed in this study [18]. In order
to reduce the effect of these factors, we only selected
patients with stage III thymoma who had undergone
complete tumor resection in a single hospital for this
analysis, but the bias due to the long duration required
for data collection still resulted in the use of different
radiation technologies (conventional RT vs. 3D-CRT/
IMRT). Conventional RT often has a large radiation
field, a poor accuracy for the target area and dose dis-
tribution, and high toxicity against normal tissues
compared to 3D-CRT/IMRT. To date, there have been
no reports regarding the use of 3D-CRT/IMRT as adju-
vant radiotherapy in the treatment of thymomas.
In the present study, we performed further investiga-
tions on the effects of 3D-CRT/IMRT as an adjuvant
therapy in patients with completely resected stage III
thymoma. The results showed that patients with 3D-
CRT/IMRT had a trend of improved 5-yr OS rate com-
pared with conventional RT (P = 0.12), and an improved
5-yr OS rate when in pairwise compared with S alone
(P = 0.049). However, when these three subgroups were
compared in pooled, difference was not statistically
significant (P = 0.2). Meantime, patients treated with 3D-
CRT/IMRT compared with patients who received con-
ventional RT had a trend of lower regional recurrence
rate (3.6% vs. 32%). However, we should note there was
long time span bias between the patients who were
treated with 3D-CRT/IMRT compared with the conven-
tional RT group. During this period, surgical skills have
also improved in addition to radiotherapy techniques.
Beyond that, the median time of follow-up in patients
with 3D-CRT/IMRT was shorter than that in patients
with conventional RT for the new radiation technique
being introduced and used after the year 2000. Conse-
quently, to further define this advantage, it will be neces-
sary to conduct a strict and appropriately planned
clinical trial to evaluate the utility of 3D-CRT/IMRT as
an adjuvant treatment after the complete resection of
thymoma.
In many reports, the doses of adjuvant RT for thym-
oma after complete resection were 30–60 Gy [19-22].
However, dose–response relationship in previous reports
have not reached a consensus. Some researchers found
that a higher dose did no good to tumor control and
survival rates. Consequently, moderate doses of adjuvant
RT was suggested [19,22]. Zhu et al. reported the out-
comes of 128 thymomas treated with doses of 45–55 Gy.
Five-year local control rates were similar between the
doses of >50 Gy and ≤ 50 Gy [19]. A study of 103 pa-
tients with completely resected thymoma followed by
radiotherapy reported by Ogawa et al. showed that a
total dose of 40 Gy was effective in preventing medias-
tinal recurrence and no dose–response relationship was
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et al. found in their study that doses in excess of 50 Gy
were associated with significantly improved DFS and OS
[21]. The similar result was found by Kundel et al. that
postoperative RT to doses above 45 Gy may improve the
DFS and OS of patients with invasive thymoma [23]. In
our study, most of the failures occurred in the pleura,
and the cude regional recurrence rates tended to de-
crease with doses >50 Gy, but the difference was not
statistically significant (P = 0.2). No survival benefit was
seen in patients of dose >50 Gy. Aboveall, controversy of
dose–response relationship for adjuvant RT of thymoma
still exists, and further evaluation by well-designed stud-
ies is required.
Conclusions
Adjuvant 3D-CRT/IMRT showed potential advantages
in improving survival and reducing relapse in patients
with stage III thymoma after complete resection.
However, for the cohort as a whole, adjuvant RT did not
significantly improve survival or reduce recurrence.
Doses of ≤ 50 Gy may be effective and could be pre-
scribed for adjuvant RT. To confirm the role of adjuvant
3D-CRT/IMRT in patients who undergo a complete re-
section of thymoma, a multicenter randomized study
should be performed.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
CF drafted the manuscript. CF, QF,YC and YZ participated in data collection,
and helped to analyze the data. QF conceived of the study, participated in
its design. All authors made substantial contributions to acquisition and
statistical analysis of data, and read and approved the final manuscript.
Acknowledgements
The authors thanked Hai-Zhen Lu, M.D., Departement of Pathology, Cancer
Hospital and Institute, Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing, for her pathologic review work for this study.
Author details
1Department of Radiation Oncology, Cancer Hospital and Institute, Chinese
Academy of Medical Sciences and Peking Union Medical College, Pan jia
yuan nan li 17#, Chao Yang District, Beijing 10021, China. 2Department of
Thoracic Surgery, Cancer Hospital and Institute, Chinese Academy of Medical
Sciences and Peking Union Medical College, Pan jia yuan nan li 17#, Chao
Yang District, Beijing 10021, China. 3Department of Radiation Oncology,
Beijing Shijitan Hospital, 10#, Yangfangdian Tieyiyuan Road, HaiDian District,
Beijing 100038, China.
Received: 24 March 2013 Accepted: 11 August 2013
Published: 13 August 2013
References
1. Blumberg D, Port JL, Weksler B, Delgado R, Rosai J, Bains MS, Ginsberg RJ,
Martini N, McCormack PM, Rusch V, et al: Thymoma: a multivariate analysis
of factors predicting survival. Ann Thorac Surg 1995, 60:908–913.
discussion 914.
2. Curran WJ Jr, Kornstein MJ, Brooks JJ, Turrisi AT 3rd: Invasive thymoma: the
role of mediastinal irradiation following complete or incomplete surgical
resection. J Clin Oncol 1988, 6:1722–1727.3. Ciernik IF, Meier U, Lutolf UM: Prognostic factors and outcome of
incompletely resected invasive thymoma following radiation therapy.
J Clin Oncol 1994, 12:1484–1490.
4. Chen YD, Feng QF, Lu HZ, Mao YS, Zhou ZM, Ou GF, Wang M, Zhao J,
Zhang HX, Xiao ZF, et al: Role of adjuvant radiotherapy for stage II
thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys
2010, 78:1400–1406.
5. Yagi K, Hirata T, Fukuse T, Yokomise H, Inui K, Ike O, Mizuno H, Aoki M,
Hitomi S, Wada H: Surgical treatment for invasive thymoma, especially
when the superior vena cava is invaded. Ann Thorac Surg 1996,
61:521–524.
6. Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of
thymomas with special reference to their clinical stages. Cancer 1981,
48:2485–2492.
7. Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y:
A review of 79 thymomas: modification of staging system and
reappraisal of conventional division into invasive and non-invasive
thymoma. Pathol Int 1994, 44:359–367.
8. Travis W, Brambilla E, Mueller-Hermelink H, Harris C: World Health
classification of tumours.Pathologe and genetics of tumours of the lung,
pleura, thymus and heart. In Tumors of Thymus. Edited by Muller-Hermelink
HK. Lyon: IARC Press; 2004:146–248.
9. Miyagaki T, Sugaya M, Miyamoto A, Nagata M, Ichimura Y, Mitsui H, Sato S:
Oral erosive lichen planus associated with thymoma treated with
etretinate. Australas J Dermatol 2013, 54:e25–e27.
10. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL:
Thymoma. Histologic subclassification is an independent prognostic
factor. Cancer 1994, 74:606–617.
11. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M,
Kiefer R, Nix W, et al: Tumor recurrence and survival in patients treated
for thymomas and thymic squamous cell carcinomas: a retrospective
analysis. J Clin Oncol 2004, 22:1501–1509.
12. Kondo K, Monden Y: Therapy for thymic epithelial tumors: a clinical study
of 1,320 patients from Japan. Ann Thorac Surg 2003, 76:878–884.
discussion 884–875.
13. Myojin M, Choi NC, Wright CD, Wain JC, Harris N, Hug EB, Mathisen DJ,
Lynch T, Carey RW, Grossbard M, et al: Stage III thymoma: pattern
of failure after surgery and postoperative radiotherapy and its
implication for future study. Int J Radiat Oncol Biol Phys 2000,
46:927–933.
14. Eralp Y, Aydiner A, Kizir A: Resectable thymoma:treatment outcome and
prognostic factors in late adolescent and adult age group. Cancer Invest
2003, 21:37–43.
15. Ruffini E, Mancuso M, Oliaro A, Casadio C, Cavallo A, Cianci R, Filosso PL,
Molinatti M, Porrello C, Cappello N, Maggi G: Recurrence of thymoma:
analysis of clinicopathologic features, treatment, and outcome. J Thorac
Cardiovasc Surg 1997, 113:55–63.
16. Korst RJ, Kansler AL, Christos PJ, Mandal S: Adjuvant radiotherapy for
thymic epithelial tumors: a systematic review and meta-analysis. Ann
Thorac Surg 2009, 87:1641–1647.
17. Haniuda M, Miyazawa M, Yoshida K, Oguchi M, Sakai F, Izuno I, Sone S:
Is postoperative radiotherapy for thymoma effective? Ann Surg 1996,
224:219–224.
18. Patel S, Macdonald OK, Nagda S, Bittner N, Suntharalingam M:
Evaluation of the role of radiation therapy in the management of
malignant Thymoma. Int J Radiat Oncol Biol Phys 2012,
82:1797–1801.
19. Zhu G, He S, Fu X, Jiang G, Liu T: Radiotherapy and prognostic factors for
thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol
Phys 2004, 60:1113–1119.
20. Cowen D, Richaud P, Mornex F, Bachelot T, Jung GM, Mirabel X, Marchal C,
Lagrange JL, Rambert P, Chaplain G, et al: Thymoma: results of a
multicentric retrospective series of 149 non-metastatic irradiated
patients and review of the literature. FNCLCC trialists. Federation
nationale des centres de lutte contre le cancer. Radiother Oncol 1995,
34:9–16.
21. Harnath T, Marx A, Strobel P, Bolke E, Willers R, Gripp S: Thymoma-a
clinico-pathological long-term study with emphasis on histology and
adjuvant radiotherapy dose. J Thorac Oncol 2012, 7:1867–1871.
22. Ogawa K, Uno T, Toita T, Onishi H, Yoshida H, Kakinohana Y, Adachi G,
Itami J, Ito H, Murayama S: Postoperative radiotherapy for patients with
Fan et al. Radiation Oncology 2013, 8:199 Page 8 of 8
http://www.ro-journal.com/content/8/1/199completely resected thymoma: a multi-institutional, retrospective review
of 103 patients. Cancer 2002, 94:1405–1413.
23. Kundel Y, Yellin A, Popovtzer A, Pfeffer R, Symon Z, Simansky DA, Oberman
B, Sadezki S, Brenner B, Catane R, Levitt ML: Adjuvant radiotherapy for
thymic epithelial tumor: treatment results and prognostic factors. Am J
Clin Oncol 2007, 30:389–394.
doi:10.1186/1748-717X-8-199
Cite this article as: Fan et al.: Postoperative radiotherapy for completely
resected Masaoka stage III thymoma: a retrospective study of 65 cases from
a single institution. Radiation Oncology 2013 8:199.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
